Alector (ALEC) Income from Continuing Operations (2018 - 2026)
Alector (ALEC) posted quarterly Income from Continuing Operations of 22930000.0 for Q1 2026, up 43.34% year-over-year from 15996690.86 in Q1 2025, and up 38.19% quarter-over-quarter from 37099000.0 in Q4 2025.
Alector (ALEC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Income from Continuing Operations for 9 consecutive years, with 22930000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 43.34% year-over-year to 22930000.0; the TTM figure through Mar 2026 stood at 125220000.0 (down 1.44% YoY), while the FY2025 annual figure was 142761000.0, down 19.92% from the prior year.
- Income from Continuing Operations grew to 22930000.0 in Q1 2026 per ALEC's latest filing, from 37099000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9883000.0 in Q2 2022 and bottomed at 52428000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 31929294.12 across 5 years, with a median of 37099000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 117.92% — and 2024, when it tumbled 2912.8%.
- Alector's Income from Continuing Operations stood at 52428000.0 in 2022, then surged by 31.73% to 35791000.0 in 2023, then jumped by 94.21% to 2074000.0 in 2024, then tumbled by 1688.77% to 37099000.0 in 2025, then jumped by 38.19% to 22930000.0 in 2026.
- Business Quant data shows ALEC's Income from Continuing Operations at 22930000.0 in Q1 2026, 37099000.0 in Q4 2025, and 34667000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - | -22.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.99 Mn |
| Mar 31, 2026 | -22.93 Mn |
| Dec 31, 2025 | -37.10 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -42.22 Mn |
| Jun 30, 2024 | -38.68 Mn |
| Mar 31, 2024 | -36.08 Mn |
| Dec 31, 2023 | -35.79 Mn |
| Sep 30, 2023 | -44.48 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | -45.86 Mn |
| Dec 31, 2022 | -52.43 Mn |
| Sep 30, 2022 | -46.15 Mn |
| Jun 30, 2022 | 9.88 Mn |
| Mar 31, 2022 | -44.62 Mn |
| Dec 31, 2021 | -47.98 Mn |
| Sep 30, 2021 | 126.60 Mn |